Delivery of rSLPI in a liposomal carrier for inhalation provides protection against cathepsin L degradation

References

• Adcock IM. Steroid resistance in asthma. Molecular mechanisms. Am J Respir Crit Care Med 1996; 154: S58–S61
   Google Scholar
• Amselem S, Gabizon A, Barenholz Y. Optimization and upscaling of doxorubicin-containing liposomes for clinical use. J Pharm Sci 1990; 79: 1045–1052
   PubMed Web of Science ®Google Scholar
• Barrios VE, Middleton SC, Kashem MA, Havill AM, Toombs CF, Wright CD. Tryptase mediates hyperresponsiveness in isolated guinea pig bronchi. Life Sci 1998; 63: 2295–2303
   PubMedGoogle Scholar
• Bergenfeldt M, Bjork P, Ohlsson K. The elimination of secretory leukocyte protease inhibitor (SLPI) after intravenous injection in dog and man. Scand J Clin Lab Invest 1990; 50: 729–737
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Haldar S. The effects of cholesterol inclusion on the vesicular membranes of cationic lipids. Biochim Biophys Acta 1996; 1283: 21–30
   PubMedGoogle Scholar
• Bhavane R, Karathanasis E, Annapragada AV. Agglomerated vesicle technology: A new class of particles for controlled and modulated pulmonary drug delivery. J Contr Rel 2003; 93: 15–28
   PubMed Web of Science ®Google Scholar
• Bi R, Zhang N. Liposomes as a carrier for pulmonary delivery of peptides and proteins. J Biomed Nanotechnol 2007; 3: 332
   Web of Science ®Google Scholar
• Bridges P, Taylor KMG. Nebulisers for the generation of liposomal aerosols. Int J Pharm 1998; 173: 117–125
   Web of Science ®Google Scholar
• Clark JM, Whitney RR, Olsen SJ, George RJ, Swerdel MR, Kunselman L, et al. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Antimicrob Agents Chemother 1991; 35: 615–621
   PubMed Web of Science ®Google Scholar
• Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res 1991; 8: 1079–1086
   PubMed Web of Science ®Google Scholar
• de Haan A, Groen G, Prop J, van Rooijen N, Wilschut J. Mucosal immunoadjuvant activity of liposomes: Role of alveolar macrophages. Immunology 1996; 89: 488–493
   PubMed Web of Science ®Google Scholar
• Elhissi AM, Faizi M, Naji WF, Gill HS, Taylor KM. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 2007; 334: 62–70
   PubMed Web of Science ®Google Scholar
• Fan M, Xu S, Xia S, Zhang X. Effect of different preparation methods on physicochemical properties of salidroside liposomes. J Agric Food Chem 2007; 55: 3089–3095
   PubMed Web of Science ®Google Scholar
• Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977; 59: 221–226
   PubMed Web of Science ®Google Scholar
• Forteza RM, Ahmed A, Lee T, Abraham WM. Secretory leukocyte protease inhibitor, but not alpha-1 protease inhibitor, blocks tryptase-induced bronchoconstriction. Pulm Pharmacol Ther 2001; 14: 107–110
   PubMedGoogle Scholar
• Freise CE, Liu T, Hong K, Osorio RW, Papahadjopoulos D, Ferrell L, et al. The increased efficacy and decreased nephrotoxicity of a cyclosporine liposome. Transplantation 1994; 57: 928–932
   PubMed Web of Science ®Google Scholar
• Fryksmark U, Ohlsson K, Polling A, Tegner H. Distribution of antileukoprotease in upper respiratory mucosa. Ann Otol Rhinol Laryngol 1982; 91: 268–271
   PubMed Web of Science ®Google Scholar
• Garg M, Dutta T, Jain NK. Stability study of stavudine-loaded O-palmitoyl-anchored carbohydrate-coated liposomes. AAPS PharmSciTech 2007; 8: Article 38
   PubMedGoogle Scholar
• Gavalda J, Martin MT, Lopez P, Gomis X, Ramirez JL, Rodriguez D, et al. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis. Antimicrob Agents Chemother 2005; 49: 3028–3030
   PubMed Web of Science ®Google Scholar
• Gavalda J, Martin T, Lopez P, Gomis X, Ramirez JL, Rodriguez D, et al. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis. Clin Microbiol Infect 2005; 11: 999–1004
   PubMedGoogle Scholar
• Gillissen A, Birrer P, McElvaney NG, Buhl R, Vogelmeier C, Hoyt RF, Jr, et al. Recombinant secretory leukoprotease inhibitor augments glutathione levels in lung epithelial lining fluid. J Appl Physiol 1993; 75: 825–832
   PubMed Web of Science ®Google Scholar
• Greene CM, McElvaney NG, O’Neill SJ, Taggart CC. Secretory leucoprotease inhibitor impairs Toll-like receptor 2- and 4-mediated responses in monocytic cells. Infect Immun 2004; 72: 3684–3687
   PubMed Web of Science ®Google Scholar
• Griffiths GD, Phillips GJ, Bailey SC. Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 1999; 17: 2562–2568
   PubMed Web of Science ®Google Scholar
• Gruber SA, Venkataram S, Canafax DM, Cipolle RJ, Bowers L, Elsberry D, McGuiggan D, Hynes PE, Ritz JA, Gould FH, Matas A, Hrushesky WJM, Rahman YE. Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. Pharm Res 1989; 6: 601–607
   PubMedGoogle Scholar
• Huang YY, Wang CH. Pulmonary delivery of insulin by liposomal carriers. J Contr Rel 2006; 113: 9–14
   PubMed Web of Science ®Google Scholar
• Jin FY, Nathan C, Radzioch D, Ding A. Secretory leukocyte protease inhibitor: A macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997; 88: 417–426
   PubMed Web of Science ®Google Scholar
• Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 542–548
   PubMed Web of Science ®Google Scholar
• Khanna C, Hasz DE, Klausner JS, Anderson PM. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies. Clin Cancer Res 1996; 2: 721–734
   PubMed Web of Science ®Google Scholar
• Kottyan LC, Collier AR, Niese KA, Radu CO, Witte ON, Rothenberg ME, et al. Eosinophils respond to acidic environments with cAMP generation in a TDAG8-dependent manner. J Allergy Clin Immunol 2007; 119: S217
   Google Scholar
• Lasic DD. Novel applications of liposomes. Trends Biotechnol 1998; 16: 307–321
   PubMed Web of Science ®Google Scholar
• Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999; 154: 239–247
   PubMed Web of Science ®Google Scholar
• Letsou GV, Safi HJ, Reardon MJ, Ergenoglu M, Li Z, Klonaris CN, et al. Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression. Ann Thorac Surg 1999; 68: 2044–2048
   PubMed Web of Science ®Google Scholar
• Lutwyche P, Cordeiro C, Wiseman DJ, St-Louis M, Uh M, Hope MJ, et al. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother 1998; 42: 2511–2520
   PubMed Web of Science ®Google Scholar
• Malvern Instruments Ltd. 2003. HPPS Operators Guide Man0314 Issue 2.0.: Malvern Instruments Ltd. New York: Dover Publications Inc. p A.1.
   Google Scholar
• Manosroi A, Podjanasoonthon K, Manosroi J. Stability and release of topical tranexamic acid liposome formulations. J Cosmet Sci 2002; 53: 375–386
   PubMed Web of Science ®Google Scholar
• McCullough HN, Juliano RL. Organ-selective action of an antitumor drug: Pharmacologic studies of liposome-encapsulated beta-cytosine arabinoside administered via the respiratory system of the rat. J Natl Cancer Inst 1979; 63: 727–731
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993; 148: 1056–1060
   PubMed Web of Science ®Google Scholar
• McElvaney NG, Nakamura H, Birrer P, Hebert CA, Wong WL, Alphonso M, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J Clin Invest 1992; 90: 1296–1301
   PubMed Web of Science ®Google Scholar
• McMullen TP, Lewis RN, McElhaney RN. Differential scanning calorimetric study of the effect of cholesterol on the thermotropic phase behavior of a homologous series of linear saturated phosphatidylcholines. Biochemistry 1993; 32: 516–522
   PubMed Web of Science ®Google Scholar
• McNeely TB, Dealy M, Dripps DJ, Orenstein JM, Eisenberg SP, Wahl SM. Secretory leukocyte protease inhibitor: A human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. J Clin Invest 1995; 96: 456–464
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 2001; 47: 165–196
   PubMed Web of Science ®Google Scholar
• Mooren HW, Kramps JA, Franken C, Meijer CJ, Dijkman JA. Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung. Thorax 1983; 38: 180–183
   PubMed Web of Science ®Google Scholar
• Morimoto Y, Adachi Y. Pulmonary uptake of liposomal phosphatidylcholine upon intratracheal administration to rats. Chem Pharm Bull (Tokyo) 1982; 30: 2248–2251
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst 1995; 12: 151–231
   PubMed Web of Science ®Google Scholar
• Niven RW, Schreier H. Nebulization of liposomes. I. Effects of lipid composition. Pharm Res 1990; 7: 1127–1133
   PubMed Web of Science ®Google Scholar
• Niven RW, Speer M, Schreier H. Nebulization of liposomes. II. The effects of size and modeling of solute release profiles. Pharm Res 1991; 8: 217–221
   PubMed Web of Science ®Google Scholar
• Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VM, Waldrep JC, Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest 1998; 113: 1573–1579
   PubMed Web of Science ®Google Scholar
• Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 1980; 104: 10–14
   PubMed Web of Science ®Google Scholar
• Stolk J, Camps J, Feitsma HI, Hermans J, Dijkman JH, Pauwels EK. Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor. Thorax 1995; 50: 645–650
   PubMedGoogle Scholar
• Suarez S, Hickey AJ. Drug properties affecting aerosol behavior. Respir Care 2000; 45: 652–666
   PubMedGoogle Scholar
• Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 1976; 17: 565–577
   PubMed Web of Science ®Google Scholar
• Swallow CJ, Grinstein S, Rotstein OD. Lipopolysaccharide impairs macrophage cytoplasmic pH regulation under conditions simulating the inflammatory microenvironment. J Leukoc Biol 1992; 52: 395–399
   PubMedGoogle Scholar
• Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000; 275: 27258–27265
   PubMed Web of Science ®Google Scholar
• Taggart CC, Greene CM, McElvaney NG, O’Neill S. Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IkappaBalpha degradation without affecting phosphorylation or ubiquitination. J Biol Chem 2002; 277: 33648–33653
   PubMed Web of Science ®Google Scholar
• Taggart CC, Lowe GJ, Greene CM, Mulgrew AT, O’Neill SJ, Levine RL, et al. Cathepsin B, L, and S cleave and inactivate secretory leucoprotease inhibitor. J Biol Chem 2001; 276: 33345–33352
   PubMed Web of Science ®Google Scholar
• Takahashi H, Ishidoh K, Muno D, Ohwada A, Nukiwa T, Kominami E, et al. Cathepsin L activity is increased in alveolar macrophages and bronchoalveolar lavage fluid of smokers. Am Rev Respir Dis 1993; 147: 1562–1568
   PubMed Web of Science ®Google Scholar
• Takeyabu K, Betsuyaku T, Nishimura M, Yoshioka A, Tanino M, Miyamoto K, et al. Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur Respir J 1998; 12: 1033–1039
   PubMed Web of Science ®Google Scholar
• Taylor KM, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm Res 1989; 6: 633–636
   PubMed Web of Science ®Google Scholar
• Taylor KMG, Taylor G, Kellaway IW, Stevens J. The stability of liposomes to nebulisation. Int J Pharm 1990; 58: 57–61
   Web of Science ®Google Scholar
• Vogelmeier C, Buhl R, Hoyt RF, Wilson E, Fells GA, Hubbard RC, et al. Aerosolization of recombinant SLPI to augment antineutrophil elastase protection of pulmonary epithelium. J Appl Physiol 1990; 69: 1843–1848
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Gillissen A, Buhl R. Use of secretory leukoprotease inhibitor to augment lung antineutrophil elastase activity. Chest 1996; 110(6 Suppl)261S–266S
   Google Scholar
• Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J Liposome Res 2006; 16: 113–125
   PubMed Web of Science ®Google Scholar
• Wright CD, Havill AM, Middleton SC, Kashem MA, Lee PA, Dripps DJ, et al. Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma. J Pharmacol Exp Ther 1999; 289: 1007–1014
   PubMed Web of Science ®Google Scholar
• Wyde PR, Six HR, Wilson SZ, Gilbert BE, Knight V. Activity against rhinoviruses, toxicity, and delivery in aerosol of enviroxime in liposomes. Antimicrob Agents Chemother 1988; 32: 890–895
   PubMed Web of Science ®Google Scholar
• Yang J, Zhu J, Sun D, Ding A. Suppression of macrophage responses to bacterial lipopolysaccharide (LPS) by secretory leukocyte protease inhibitor (SLPI) is independent of its anti-protease function. Biochim Biophys Acta 2005; 1745: 310–317
   PubMed Web of Science ®Google Scholar
• Yohannes G, Pystynen KH, Riekkola ML, Wiedmer SK. Stability of phospholipid vesicles studied by asymmetrical field-flow fractionation and capillary electrophoresis. Anal Chim Acta 2006; 560: 50–56
   Web of Science ®Google Scholar
• Zhang Y, DeWitt DL, McNeely TB, Wahl SM, Wahl LM. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinases. J Clin Invest 1997; 99: 894–900
   PubMed Web of Science ®Google Scholar